45.76
-0.87 (-1.87%)
| Previous Close | 46.63 |
| Open | 45.95 |
| Volume | 411,298 |
| Avg. Volume (3M) | 795,422 |
| Market Cap | 2,495,096,064 |
| Price / Earnings (Forward) | 23.42 |
| Price / Sales | 2.00 |
| Price / Book | 2.46 |
| 52 Weeks Range | |
| Earnings Date | 29 Jul 2025 - 4 Aug 2025 |
| Profit Margin | -17.42% |
| Operating Margin (TTM) | 15.54% |
| Diluted EPS (TTM) | -4.07 |
| Quarterly Revenue Growth (YOY) | 7.40% |
| Quarterly Earnings Growth (YOY) | 242.10% |
| Total Debt/Equity (MRQ) | 65.54% |
| Current Ratio (MRQ) | 1.58 |
| Operating Cash Flow (TTM) | 197.02 M |
| Levered Free Cash Flow (TTM) | 782.12 M |
| Return on Assets (TTM) | 4.55% |
| Return on Equity (TTM) | -19.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Mixed |
| Medical Devices (Global) | Bearish | Mixed | |
| Stock | LivaNova PLC | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.88 |
|
UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 0.33% |
| % Held by Institutions | 102.63% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Redmile Group, Llc | 31 Mar 2025 | 1,014,139 |
| Exoduspoint Capital Management, Lp | 31 Mar 2025 | 992,447 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 64.00 (Needham, 39.86%) | Buy |
| Median | 60.50 (32.21%) | |
| Low | 55.00 (Barclays, 20.19%) | Hold |
| Average | 60.00 (31.12%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 44.27 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wolfe Research | 20 May 2025 | 60.00 (31.12%) | Buy | 44.88 |
| Needham | 13 May 2025 | 64.00 (39.86%) | Buy | 44.06 |
| 17 Mar 2025 | 64.00 (39.86%) | Buy | 41.41 | |
| Baird | 08 May 2025 | 61.00 (33.30%) | Buy | 44.07 |
| Barclays | 08 May 2025 | 55.00 (20.19%) | Hold | 44.07 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |